Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:149789650" >
Randomised controll...
Randomised controlled trial of the short-term effects of osmotic-release oral system methylphenidate on symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder: CIAO-II study
-
Asherson, PJ (författare)
-
Johansson, L (författare)
-
Holland, R (författare)
-
visa fler...
-
Bedding, M (författare)
-
Forrester, A (författare)
-
Giannulli, L (författare)
-
- Ginsberg, Y (författare)
- Karolinska Institutet
-
Howitt, S (författare)
-
Kretzschmar, I (författare)
-
Lawrie, SM (författare)
-
Marsh, C (författare)
-
Kelly, C (författare)
-
Mansfield, M (författare)
-
McCafferty, C (författare)
-
Khan, K (författare)
-
Muller-Sedgwick, U (författare)
-
Strang, J (författare)
-
Williamson, G (författare)
-
Wilson, L (författare)
-
Young, S (författare)
-
Landau, S (författare)
-
Thomson, LDG (författare)
-
visa färre...
-
(creator_code:org_t)
- 2022-06-03
- 2023
- Engelska.
-
Ingår i: The British journal of psychiatry : the journal of mental science. - : Royal College of Psychiatrists. - 1472-1465. ; 222:1, s. 7-17
- Relaterad länk:
-
http://kipublication...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Research has shown that 20–30% of prisoners meet the diagnostic criteria for attention-deficit hyperactivity disorder (ADHD). Methylphenidate reduces ADHD symptoms, but effects in prisoners are uncertain because of comorbid mental health and substance use disorders.AimsTo estimate the efficacy of an osmotic-release oral system methylphenidate (OROS-methylphenidate) in reducing ADHD symptoms in young adult prisoners with ADHD.MethodWe conducted an 8-week parallel-arm, double-blind, randomised placebo-controlled trial of OROS-methylphenidate versus placebo in male prisoners (aged 16–25 years) meeting the DSM-5 criteria for ADHD. Primary outcome was ADHD symptoms at 8 weeks, using the investigator-rated Connors Adult ADHD Rating Scale (CAARS-O). Thirteen secondary outcomes were measured, including emotional dysregulation, mind wandering, violent attitudes, mental health symptoms, and prison officer and educational staff ratings of behaviour and aggression.ResultsIn the OROS-methylphenidate arm, mean CAARS-O score at 8 weeks was estimated to be reduced by 0.57 points relative to the placebo arm (95% CI −2.41 to 3.56), and non-significant. The responder rate, defined as a 20% reduction in CAARS-O score, was 48.3% for the OROS-methylphenidate arm and 47.9% for the placebo arm. No statistically significant trial arm differences were detected for any of the secondary outcomes. Mean final titrated dose was 53.8 mg in the OROS-methylphenidate arm.ConclusionsADHD symptoms did not respond to OROS-methylphenidate in young adult prisoners. The findings do not support routine treatment with OROS-methylphenidate in this population. Further research is needed to evaluate effects of higher average dosing and adherence to treatment, multi-modal treatments and preventative interventions in the community.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Asherson, PJ
-
Johansson, L
-
Holland, R
-
Bedding, M
-
Forrester, A
-
Giannulli, L
-
visa fler...
-
Ginsberg, Y
-
Howitt, S
-
Kretzschmar, I
-
Lawrie, SM
-
Marsh, C
-
Kelly, C
-
Mansfield, M
-
McCafferty, C
-
Khan, K
-
Muller-Sedgwick, ...
-
Strang, J
-
Williamson, G
-
Wilson, L
-
Young, S
-
Landau, S
-
Thomson, LDG
-
visa färre...
- Artiklar i publikationen
-
The British jour ...
-
The British Jour ...
- Av lärosätet
-
Karolinska Institutet